This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The principle used in the analysis of effectiveness (intention to treat or treatment completers only) was not explicitly reported. The health outcome measures were the rate of recall mammography (subdivided into recall due to clinical findings, technical difficulties, and/or suspected cancer on mammography), cases of breast cancer revealed, the rate of false positives, the size of tumours, the proportion of breast cancer patients having axillary lymph node metastases, the proportion of breast cancer patients undergoing breast conserving strategy (BCS) including postoperative radiotherapy, and a modified radical mastectomy (MRM).
Effectiveness results
The rate of recall mammography was 6% (subdivided into recall due to clinical findings, 0.4%; technical difficulties, 0.9%; and/or suspected cancer on mammography, 4.7%). 337 cases of breast cancer were revealed giving a detection rate of 0.7%. In terms of the rate of false positives, five out of six suspected cases ended up not having breast cancer. The size of tumours was less than or equal to 15 mm, while 18% of breast cancer patients had axillary lymph node metastases. This suggested that the NMP target of a 30% reduction in breast cancer mortality would be achievable. Of the 337 cases of breast cancer detected and treated, 42% had a breast conserving strategy (BCS) including postoperative radiotherapy (2-opposite tangential field technique, 50 Gy in 25 fractions), the others were treated with a modified radical mastectomy (MRM) and an axillary lymph node dissection.
Clinical conclusions
A 30% reduction in breast cancer death was calculated from this survey.
Modelling
A model was used to estimate the costs and future benefits of screening although the details of the model employed were not given. The description of the non-screening strategy was based on national data on assessment and treatment.
Outcomes assessed in the review
The following outcomes were assessed from a review of the literature: frequency of stage I and II breast cancers, median life expectancy for women aged 60 and 69, proportion of breast cancer cases occurring in women aged over 60 years, proportion of breast cancers occurring in premenopausal women and corresponding rate of axillary lymph node involvement, proportion of postmenopausal women having 4 or more affected lymph nodes, median life expectancy for patients saved from the death from breast cancer by screening, median delay time for the diagnosis of breast cancer in the no-screening strategy, median survival when contracting an incurable breast cancer, annual number of women dying in Norway because of breast cancer, frequency of MRM in the no-screening strategy, frequency of adjuvant hormonal therapy (AHT) in the screening and non-screening situation, proportion of patients with breast cancer fulfilling the criteria for adjuvant chemotherapy, frequency of adjuvant chemotherapy (CMF-nine cycles) in the screening and no-screening situation, risk of a new breast cancer in the BCS group, mortality rate due to other causes of death during 10 year follow-up, from 60 to 70 years, and proportion of patients going through 10 years follow-up.
